Review of NICE Technology Appraisal Guidance No. 179; Sunitinib for the treatment of gastrointestinal stromal tumours

Proposal to move guidance to the static list

As you may be aware the planned date for review of the above guidance is November 2011. 

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal. 

Since the previous guidance was issued, no new interventions have come to market and the marketing authorisation for sunitinib has not changed.  Very limited new evidence has become available and it does not suggest that the TA179 recommendations would change if the appraisal were subject to review. In addition, the manufacturer has no plans to change the existing patient access scheme (PAS) and the Department of Health is content for the PAS to continue in its current format therefore no review of the PAS is required.

Consequently, it is proposed that the guidance is placed on the static list.

Topics on the static list may be transferred back to the active list for further consideration if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance. 

Please see appendix A for a full list of the organisations we have contacted. 

November 2011